Jump to main content
Jump to site search

Issue 42, 2017
Previous Article Next Article

Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization

Author affiliations

Abstract

Trastuzumab (Herceptin®) is an FDA-approved therapeutic antibody currently employed in the treatment of metastatic stages of breast cancer. Herein, we propose a simple, fast and cost-effective methodology to conjugate trastuzumab with 22-mer 5′ thiol-modified oligonucleotides using a bifunctional crosslinker. The conjugates were successfully characterized by MALDI-ToF MS and SDS-PAGE, obviating the need for enzymatic digestion and difficult chromatographic separations. Furthermore, ELISA was performed to ensure that trastuzumab activity is not affected by oligonucleotide conjugation.

Graphical abstract: Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization

Back to tab navigation

Supplementary files

Article information


Submitted
03 Sep 2017
Accepted
09 Oct 2017
First published
09 Oct 2017

Org. Biomol. Chem., 2017,15, 8923-8928
Article type
Paper

Decoration of trastuzumab with short oligonucleotides: synthesis and detailed characterization

A. M. Carvalho, A. Manicardi, C. V. Montes, S. B. Gunnoo, R. J. Schneider and A. Madder, Org. Biomol. Chem., 2017, 15, 8923
DOI: 10.1039/C7OB02216F

Social activity

Search articles by author

Spotlight

Advertisements